198 related articles for article (PubMed ID: 29644833)
1. GROWTH-INHIBITORY EFFECTS OF FARNESOL AGAINST SCEDOSPORIUM BOYDII AND LOMENTOSPORA PROLIFICANS.
Pumeesat P; Wongsuk T; Muangkaew W; Luplertlop N
Southeast Asian J Trop Med Public Health; 2017 Jan; 48(1):170-8. PubMed ID: 29644833
[TBL] [Abstract][Full Text] [Related]
2. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
Wiederhold NP; Law D; Birch M
J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
[TBL] [Abstract][Full Text] [Related]
3.
Furnica DT; Dittmer S; Scharmann U; Meis JF; Steinmann J; Rath PM; Kirchhoff L
Microbiol Spectr; 2023 Jun; 11(3):e0513022. PubMed ID: 37017567
[TBL] [Abstract][Full Text] [Related]
4. N-Chlorotaurine Exhibits Fungicidal Activity against Therapy-Refractory Scedosporium Species and Lomentospora prolificans.
Lackner M; Binder U; Reindl M; Gönül B; Fankhauser H; Mair C; Nagl M
Antimicrob Agents Chemother; 2015 Oct; 59(10):6454-62. PubMed ID: 26239996
[TBL] [Abstract][Full Text] [Related]
5. Conidial germination in Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans: influence of growth conditions and antifungal susceptibility profiles.
Mello TP; Aor AC; Oliveira SS; Branquinha MH; Santos AL
Mem Inst Oswaldo Cruz; 2016 Jun; 0(7):0. PubMed ID: 27355215
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.
Biswas C; Law D; Birch M; Halliday C; Sorrell TC; Rex J; Slavin M; Chen SC
Med Mycol; 2018 Nov; 56(8):1050-1054. PubMed ID: 29370408
[TBL] [Abstract][Full Text] [Related]
7. Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.
Rollin-Pinheiro R; Xisto MIDDS; de Castro-Almeida Y; Rochetti VP; Borba-Santos LP; Fontes YDS; Ferreira-Pereira A; Rozental S; Barreto-Bergter E
PLoS One; 2023; 18(2):e0280964. PubMed ID: 36735743
[TBL] [Abstract][Full Text] [Related]
8.
Georgacopoulos O; Nunnally N; Law D; Birch M; Berkow EL; Lockhart SR
Microbiol Spectr; 2023 Feb; 11(1):e0278922. PubMed ID: 36629417
[No Abstract] [Full Text] [Related]
9. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification.
Bronnimann D; Garcia-Hermoso D; Dromer F; Lanternier F; ;
Med Mycol; 2021 May; 59(5):486-497. PubMed ID: 33037432
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity against Scedosporium species and novel assays to assess antifungal pharmacodynamics against filamentous fungi.
Wiederhold NP; Lewis RE
Med Mycol; 2009 Jun; 47(4):422-32. PubMed ID: 19058049
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
12. Impact of biofilm formation and azoles' susceptibility in Scedosporium/Lomentospora species using an in vitro model that mimics the cystic fibrosis patients' airway environment.
Mello TP; Lackner M; Branquinha MH; Santos ALS
J Cyst Fibros; 2021 Mar; 20(2):303-309. PubMed ID: 33334714
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.
Rivero-Menendez O; Cuenca-Estrella M; Alastruey-Izquierdo A
J Antimicrob Chemother; 2020 Dec; 75(12):3582-3585. PubMed ID: 32856079
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of auranofin and honokiol as antifungals against
Yaakoub H; Staerck C; Mina S; Godon C; Fleury M; Bouchara JP; Calenda A
Virulence; 2021 Dec; 12(1):1076-1090. PubMed ID: 33825667
[TBL] [Abstract][Full Text] [Related]
15. Effects of Photodynamic Therapy on the Growth and Antifungal Susceptibility of Scedosporium and Lomentospora spp.
Lu Q; Sun Y; Tian D; Xiang S; Gao L
Mycopathologia; 2017 Dec; 182(11-12):1037-1043. PubMed ID: 28836110
[TBL] [Abstract][Full Text] [Related]
16. Decoding the antifungal resistance mechanisms in biofilms of emerging, ubiquitous and multidrug-resistant species belonging to the Scedosporium/Lomentospora genera.
Mello TP; Oliveira SSC; Branquinha MH; Santos ALS
Med Mycol; 2022 Jun; 60(6):. PubMed ID: 35641191
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.
Jenks JD; Seidel D; Cornely OA; Chen S; van Hal S; Kauffman C; Miceli MH; Heinemann M; Christner M; Jover Sáenz A; Burchardt A; Kemmerling B; Herbrecht R; Steinmann J; Shoham S; Gräber S; Pagano L; Deeren D; Aslam S; Taplitz R; Revankar SG; Baddley J; Mehta SR; Reed S; Slavin MA; Hoenigl M
Clin Microbiol Infect; 2020 Jun; 26(6):784.e1-784.e5. PubMed ID: 31972317
[TBL] [Abstract][Full Text] [Related]
18. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.
Gil-Lamaignere C; Roilides E; Mosquera J; Maloukou A; Walsh TJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2234-7. PubMed ID: 12069979
[TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations and susceptibility of Scedosporium/Lomentospora infections at a tertiary medical centre in Taiwan from 2014 to 2021: A retrospective cohort study.
Lao CK; Ou JH; Fan YC; Wu TS; Sun PL
Mycoses; 2023 Oct; 66(10):923-935. PubMed ID: 37449538
[TBL] [Abstract][Full Text] [Related]
20. Isolation, characterization, and antifungal susceptibility of melanin-deficient mutants of Scedosporium prolificans.
Ruiz-Díez B; Martínez-Suárez JV
Curr Microbiol; 2003 Mar; 46(3):228-32. PubMed ID: 12567248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
